IP Library › Granted Patent US 12,654,036
Granted Patent B2
US 12,654,036 · App. 16/495,177 · Granted Jun 16, 2026

Method for treating heart failure by improving ejection fraction of a patient

Inventors: Or Shabtay (Kibbutz Farod, IL); Dalit Shav (Rehovot, IL)
Assignee: SONIVIE LTD.
A61N7/00A61B18/00A61B18/0206A61B18/082A61B18/1492A61B18/24A61K31/191A61K31/343A61K31/4965A61K31/4985A61K31/506A61K31/519A61K31/53A61N2/06A61N5/1002A61N7/022A61B5/055A61B6/032A61B6/504A61B2017/00292A61B2018/00369A61B2018/00434A61B2018/0212A61B2018/1253A61B2018/126A61B2018/1807A61B2018/1861A61N2007/003A61N2007/0043A61N2007/0078
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,654,036
App. No.
16/495,177
Granted
Jun 16, 2026
Kind
B2
Abstract

A method for improving an ejection fraction of a patient in need thereof, including positioning a pulmonary artery manipulation device in a target blood vessel, within the pulmonary vasculature of the patient; and impairing the activity of at least one sympathetic nerve, nerve fiber or neuron, using the pulmonary artery manipulation device, to denervate the target blood vessel, thereby improving the ejection fraction of the patient.

Claims (13)

1 . A method for improving an ejection fraction of a patient in need thereof, the method comprising:

positioning a treatment device in a target arterial blood vessel, within a pulmonary vasculature of the patient; wherein the patient is diagnosed as having an ejection fraction of below 50%; and

impairing an activity of at least one sympathetic nerve, nerve fiber or neuron, using the treatment device, to denervate the target arterial blood vessel, wherein the impairing improves the ejection fraction of the patient, wherein the treatment device comprises an ultrasound transmission device configured to emit an ultrasound beam at a frequency of 1-20 MHz.

2 . The method of claim 1 , wherein the ejection fraction is left ventricle ejection fraction.

3 . The method of claim 1 , wherein the ejection fraction is right ventricle ejection fraction.

4 . The method of claim 1 , wherein the ultrasound beam is emitted at a frequency of 8-12 MHz.

5 . The method of claim 1 , wherein impairing the activity of at least one sympathetic nerve, nerve fiber or neuron comprises emitting an ultrasound beam from the treatment device.

6 . The method of claim 5 , wherein the ultrasound beam is an unfocused ultrasound beam.

7 . The method of claim 1 , further comprising indicating one or more side effects.

8 . The method of claim 7 , wherein the one or more side effects is selected from the group consisting of: heart rhythm disturbances, bradycardia, blot clot formation, embolism, ischemia, ischemic events, myocardial infarction, stroke, hemoptysis, hematoma, bruising, bleeding, vascular complications, arterial spasm, arterial stenosis, arterial dissection, perforation, pulmonary perforation, pseudo-aneurysm, AV-fistula, allergic reactions, reduced kidney function, pain, infection, nausea, vomit, fever, death, cardiopulmonary arrest, anxiolytics, pain medication addiction, side effects associated with pain medication used during procedure, anti-vasospasm agents used during a procedure, infection, toxicity, adverse hematology, hemorrhage, hemoptysis, pyrogenicity, damage to blood vessel wall or other body structures, pulmonary artery stenosis, nerve damage, spasm, aneurysm formation, aneurism rupture, damage to local anatomical structures, damage to cardiac plexus, damage to esophagus, damage to trachea, damage to lung, damage to vagus, bradycardia, tachycardia, partial vocal cord palsy, haemoptysis, decreased pulmonary function, hypertension, hypo-perfusion, or any combination thereof.

9 . The method of claim 1 , wherein the patient has an ejection fraction below 35%.

10 . The method of claim 1 , wherein the target arterial blood vessel is one of a pulmonary trunk, a left pulmonary artery, and a right pulmonary artery.

11 . The method of claim 1 , wherein the ultrasound beam has an intensity in a range of 30 Watts (W)/centimeter (cm) 2 to 70 W/cm 2 .

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2019
From: SHABTAY, OR; SHAV, DALIT
To: SONIVIE LTD.
Reel/Frame 050415/0029 →
Continuity (4)
Provisional Application 62473532 · Mar 20, 2017
Provisional Application 62473512 · Mar 20, 2017
Provisional Application 62473545 · Mar 20, 2017
Related Publication 20200094080A1 · Mar 26, 2020
References Cited (47)
US 6740648B2 · Ghazzi et al. · 2004 [cited by applicant]
US 6970742B2 · Mann et al. · 2005 [cited by applicant]
US 8377933B2 · Gerber et al. · 2013 [cited by applicant]
US 8715209B2 · Gertner · 2014 [cited by examiner]
US 9918776B2 · Chen · 2018 [cited by applicant]
US 20110118725A1 · Mayse · 2011 [cited by applicant]
US 20110257562A1 · Schaer · 2011 [cited by applicant]
US 20120215106A1 · Sverdlik et al. · 2012 [cited by applicant]
US 20130204068A1 · Gnanashanmugam et al. · 2013 [cited by applicant]
US 20140180277A1 · Chen · 2014 [cited by applicant]
US 20150196357A1 · Chen · 2015 [cited by applicant]
US 20150196705A1 · Brenneman et al. · 2015 [cited by applicant]
US 20160256216A1 · Chang · 2016 [cited by examiner]
US 20170027645A1 · Ben Oren et al. · 2017 [cited by applicant]
US 20170128751A1 · Gilad · 2017 [cited by examiner]
US 20200238107A1 · Shabtay · 2020 [cited by examiner]
WO 2015193889 · 2015 [cited by applicant]
WO 2016084081 · 2016 [cited by applicant]
WO 2016084081A1 · 2016 [cited by applicant]
Leopold, J. A. (2015). Catheter-based therapies for patients with medication-refractory pulmonary arterial hypertension. Circulation: Cardiovascular Interventions, 8(11). https://doi.org/10.1161/circinterventions.115.00… [cited by examiner]
Zhang, Hang, et al. “Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease.” Pulmonary circulation 6.2 (2016): 240-243. (Year: 2016). [cited by examiner]
Oral, H. (2006). Circumferential pulmonary-vein ablation for atrial fibrillation. New England Journal of Medicine, 354(21), 2289-2291. https://doi.org/10.1056/nejmc060884 (Year: 2006). [cited by examiner]
Heart failure with preserved Ejection Fraction (HFpEF). Heart Failure with Preserved Ejection Fraction (HFpEF) | Frankel Cardiovascular Center | Michigan Medicine. (Mar. 13, 2017). https://www.umcvc.org/conditions-treat… [cited by examiner]
Hynynen, K., Dennie, J., Zimmer, J. E., Simmons, W. N., Ding Sheng He, Marcus, F. I., & Aguirre, M. (1997). Cylindrical ultrasonic transducers for cardiac catheter ablation. IEEE Transactions on Biomedical Engineering, … [cited by examiner]
Becker, R., & Schoels, W. (2004). Ablation of atrial fibrillation: Energy Sources and Navigation Tools: A Review. Journal of Electrocardiology, 37, 55-62. https://doi.org/10.1016/j.jelectrocard.2004.08.016 (Year: 2004). [cited by examiner]
Hsu, L.-F., & Jaïs, P. (2004). Catheter ablation for atrial fibrillation in congestive heart failure. New England Journal of Medicine, 351(23), 2373-2383. https://doi.org/10.1056/nejmoa041018 (Year: 2004). [cited by examiner]
Pappone, C., & Augello, G. (2006). A randomized trial of circumferential pulmonary vein ablation versus antiarrhythmic drug therapy in paroxysmal atrial fibrillation. Journal of the American College of Cardiology, 48(11… [cited by examiner]
Khan, M. N., Jaïs, P., & Natale, A. (2008). Pulmonary-vein isolation for atrial fibrillation in patients with heart failure. New England Journal of Medicine, 359(17), 1778-1785. https://doi.org/10.1056/nejmoa0708234 (Ye… [cited by examiner]
Anter, E., Jessup, M., & Callans, D. J. (2009). Atrial fibrillation and heart failure. Circulation, 119(18), 2516-2525. https://doi.org/10.1161/circulationaha.108.821306 (Year: 2009). [cited by examiner]
Sinelnikov, Y. D., Fjield, T., & Sapozhnikov, O. A. (2009). The mechanism of lesion formation by focused ultrasound ablation catheter for treatment of atrial fibrillation. Acoustical Physics, 55(4-5), 647-656. https://d… [cited by examiner]
Ad, N., Henry, L., & Hunt, S. (2011). The impact of surgical ablation in patients with low ejection fraction, heart failure, and atrial fibrillation. European Journal of Cardio-Thoracic Surgery, 40(1), 70-76. https://do… [cited by examiner]
Greillier, P., Bawiec, C., Bessière, F., & Lafon, C. (2018). Therapeutic ultrasound for the heart: State of the art. IRBM, 39(4), 227-235. https://doi.org/10.1016/j.irbm.2017.11.004 (Year: 2018). [cited by examiner]
Zhang, et al (2016) Pulmonary artery denervation for treatment of a patient with pulmonary hypertension secondary to left heart disease, Pulmonary circulation 6.2: 240-243. [cited by applicant]
Chen, et al (2013) Percutaneous pulmonary artery denervation completely abolishes experimental pulmonary arterial hypertension in vivo, EuroIntervention 9.2: 269-76. [cited by applicant]
International Search Report of PCT/IL2018/050316 Completed Jun. 19, 2018; Mailed Jun. 19, 2018 9 pages. [cited by applicant]
Written Opinion of PCT/IL2018/050316 Completed Jun. 19, 2018; Mailed Jun. 19, 2018 6 pages. [cited by applicant]
Shao-Liang Chen et al (2013) Pulmonary Artery Denervation to Treat Pulmonary Arterial Hypertension, Journal of the American College of Cardiology, vol. 62, No. 12, pp. 1092. [cited by applicant]
Kalogeropoulos et al (2011) Pulmonary hypertension and right ventricular function in advanced heart failure, Congestive Heart Failure, 17(4):189-198. [cited by applicant]
Li, Bao (2013) Cardiovascular Intervention Training Course, published by People's Military Medical Press, ISBN No. 978-7-5091-6440-2, including Section 8 Intra-Aortic Ballon Counterpulsation, pp. 75-77, 26 p. [English B… [cited by applicant]
Li Yigang (2010), “Clinical Key Technology of Interventional Diagnosis and Treatment of Tachyarrhythmia,” published by Scientific and Technical Documents Publishing House, ISBN No. 978-7-5023-6528-8, including Chpt 5 Ul… [cited by applicant]
Lin Lixue (2007) “Modern Ultrasound In Cardiac Electrophysiology,” published by People's Military Medical Press, ISBN No. 978-7-5091-1206-0, including Chpt. 39, Section 2, Ultrasonic Ablation Device, pp. 689-692, 36 pag… [cited by applicant]
Natale et al.(2009) “Ventricular Tachycardia/Fibrillation Ablation: the state of the Art based on the VeniceChart International Consensus Document,” John Wiley & Sons, p. 264, fig. 14.3, 6 pages. [cited by applicant]
Zhang et al.(2014) “Perioperative Management of Cardiovascular Diseases,” published by People's Medical Publishing House, ISBN No. 987-7-117-18454-0, including Chpt 3 Section 3 Cardiac Ejection and Ventricular Afterload… [cited by applicant]
Li, Bao (2013) Cardiovascular Intervention Training Course, published by People's Military Medical Press, ISBN No. 978-7-5091-6440-2, including Section 8 Intra-Aortic Balloon Counterpulsation, pp. 75-77, 31 total p. [En… [cited by applicant]
Li Yigang (2010), “Clinical Key Technology of Interventional Diagnosis and Treatment of Tachyarrhythmia,” published by Scientific and Technical Documents Publishing House, ISBN No. 978-7-5023-6528-8, including Chpt 5, U… [cited by applicant]
Lin Lixue (2007) “Modern Ultrasound in Cardiac Electrophysiology,” published by People's Military Medical Press, ISBN No. 978-7-5091-1206-0, including Chpt. 39, Section 2, Ultrasonic Ablation Device, pp. 689-692, 45 tot… [cited by applicant]
Zhang et al(2014) “Perioperative Management of Cardiovascular Diseases,” published by People's Medical Publishing House, ISBN No. 987-7-117-18454-0, including Chpt 3, Section 3, Cardiac Ejection and Ventricular Afterloa… [cited by applicant]